1. Novel Expanding Renal Cell Carcinoma Biomarkers
- Author
-
M. Carmen Mir, Francesco Claps, Claps, Francesco, and Mir, M. Carmen
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,diagnosis ,Usually asymptomatic ,Renal cell carcinoma ,biomarker ,prognosis ,survival ,Proteomics ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Liquid biopsy ,General Environmental Science ,Radical treatment ,business.industry ,Disease progression ,Cancer ,medicine.disease ,diagnosi ,030104 developmental biology ,030220 oncology & carcinogenesis ,General Earth and Planetary Sciences ,Biomarker (medicine) ,business ,prognosi - Abstract
Identification of reliable molecular biomarkers that can complement clinical practice represents a fascinating challenge in any cancer field. Renal tumors are usually asymptomatic and incidentally identified during imaging studies undertaken for unrelated causes. However, in 25% to 30% of patients the first diagnosis is accompanied by symptoms and associated with distant metastasis. Thus, early diagnosis may reduce the risk of disease progression also avoiding side effects of inadequate treatments. Moreover, the ability to categorize patients' risk of recurrence after radical treatment, or even predict benefit from a target therapy, represents a compelling challenge. Here we review the current state-of-the-art on RCC biomarkers, particularly focusing on the new approaches of genomics, liquid biopsy, proteomics, and metabolomics.
- Published
- 2021
- Full Text
- View/download PDF